Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...
CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...
18h
Stocktwits on MSNRegeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same PageShares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immuneering (IMRX – Research Report) and Palatin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results